Abiraterone acetate (AA) is a potent selective inhibitor of cytochrome P450 (CYP) 17, a key enzyme involved in testosterone synthesis. Due to this inhibition, the production of androgens by endocrine tissues decreases. Therefore, this oral hormone therapy is used in castration-resistant prostate cancer combined with prednisone/prednisolone, with a significant increase in overall survival. Common side effects of AA include hypertension, hypokalaemia, peripheral oedema and urinary tract infections.
http://ift.tt/2CauJl8
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου